NOT MEDICAL ADVICE

PT-141

Estimated Market Price
$99.99 $114.99
Based on verified supplier pricing for research-grade compounds
Peptide for sexual health and libido enhancement. Works on the central nervous system for natural arousal support.
How it works

Activates melanocortin-4 receptors in the brain to stimulate sexual desire and arousal directly through the central nervous system, rather than just increasing blood flow like Viagra.

Performance

Sexual Health

popular

What to Expect
30–45 min Flushing and warmth indicate MC4R activation beginning. Warm flush in the face and chest; slight nausea possible.
1–2 hours Peak arousal effects; enhanced desire and responsiveness. Heightened arousal and desire; effects feel natural, not forced.
3–6 hours Effects gradually tapering; mild nausea may occur initially. Gradually winding down; some people feel slightly nauseous.
24 hours Full clearance; safe to re-dose if needed next day. Back to normal; no lingering effects.

Verified Suppliers

For research purposes only. These suppliers have been independently verified by PepSpace. We do not process sales directly.

PepSpace is not affiliated with any listed supplier
Protocol & Dosage
Typical Dosage 1.75 mg SC as needed
Administration Subcutaneous injection
Schedule As needed, 45 min before activity; max 1 dose per 24 hours
Protocol Duration PRN (as needed)
Half-Life ~2.7 hours
Side Effects & Safety
Tolerability Profile Moderate

Notable side effects likely; manageable with proper awareness

Common Side Effects

  • Nausea~40%
  • Facial flushing~20%
  • Headache~11%
  • Injection site reactions~6%

Less Common

  • Vomiting~5%
  • Blood pressure elevation (transient)~3%
  • Dizziness~2%
  • Fatigueoccasional

Rare / Serious

  • Skin hyperpigmentation (repeated use)rare
  • Paresthesia (tingling)rare

Discontinue If

  • Severe blood pressure spike or chest pain
  • Persistent vomiting lasting more than 2 hours
  • Severe allergic reaction (swelling, hives, difficulty breathing)

Contraindications

  • Uncontrolled hypertension
  • Pregnancy or breastfeeding
  • Concurrent use of blood pressure medications
  • Cardiovascular disease

Data note: FDA-approved (Vyleesi, 2019). Nausea is the most common reason for discontinuation. Max 8 doses/month recommended.

Always consult a qualified healthcare professional before use. This information is for research reference only and does not constitute medical advice.

Ask about PT-141
Send us a message

Call us
+1 (518) 327-4392
Business hours
Monday – Friday 9:00 AM – 6:00 PM EST
Saturday 10:00 AM – 2:00 PM EST
Sunday Closed

You can also reach us via or .

How to Apply

1

Gather

Peptide vial, BAC water, alcohol swabs, insulin syringe

2

Sanitize

Wipe tops of both vials with alcohol swabs

3

Draw

Pull 1–2 mL of BAC water into syringe

4

Add Water

Release water slowly along vial wall, not directly on powder

5

Swirl

Roll between palms until dissolved. Never shake.

6

Store

Refrigerate 2–8°C, use within 30 days

Frequently Asked Questions

Yes. Bacteriostatic water (BAC water) is required to reconstitute lyophilized (freeze-dried) peptides. It contains 0.9% benzyl alcohol which prevents bacterial growth, keeping your reconstituted peptide safe for multiple uses over up to 30 days.

Unreconstituted: store at -20°C (freezer) for long-term, or 2–8°C (fridge) for short-term. After reconstitution: always refrigerate at 2–8°C and use within 30 days. Keep away from direct sunlight.

Results vary by individual and protocol. In research settings, measurable effects are typically observed within 1–4 weeks depending on the specific peptide, dosage, and application. Consult a qualified professional for guidance.

Verified suppliers typically include a full third-party COA verifying purity (99%+), identity, and sterility. We recommend only sourcing from vendors that provide batch-specific testing data.

We list verified suppliers above that have been independently reviewed for product quality, testing transparency, and shipping reliability. Always verify COA data before sourcing.

Compound Profile

Scientific data & classification for PT-141

Also Known As Bremelanotide, Vyleesi
Classification Cyclic Heptapeptide · Melanocortin Agonist
Sequence Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-OH (cyclic)
Molecular Formula C₅₀H₆₈N₁₄O₁₀
Molecular Weight 1,025.18 Da
CAS Number 189691-06-3
Half-Life ~2.7 hours
Origin Synthetic melanocortin receptor agonist derived from Melanotan II
Administration Subcutaneous injection
Status FDA Approved (2019) - hypoactive sexual desire disorder in women
Mechanism of Action Activates melanocortin-4 receptors in the brain to stimulate sexual desire and arousal directly through the central nervous system, rather than just increasing blood flow like Viagra.
Research Overview Bremelanotide (PT-141) is a cyclic heptapeptide melanocortin receptor agonist that became the first FDA-approved treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women when it received regulatory clearance in June 2019 under the trade name Vyleesi. The compound's development history traces back to an unexpected observation during clinical trials of Melanotan II (MT-II) as a sunless tanning agent in the 1990s at the University of Arizona - male participants reported spontaneous penile erections, and subsequent investigation identified the melanocortin-4 receptor (MC4R) in the central nervous system as the mediating target for sexual arousal effects. PT-141 was developed as a metabolite and structural refinement of MT-II, optimized for MC4R selectivity while reducing activity at MC1R (tanning) and MC3R/MC5R. The compound's mechanism of action is fundamentally distinct from phosphodiesterase-5 inhibitors such as sildenafil (Viagra) - whereas PDE5 inhibitors act peripherally on penile vascular smooth muscle to facilitate erection in response to existing arousal, PT-141 acts centrally within the hypothalamus and limbic system to modulate the neural circuitry of sexual desire and arousal itself. The RECONNECT Phase III clinical trial program in women with HSDD demonstrated statistically significant improvements in the number of satisfying sexual events and sexual desire scores compared to placebo, with the most common side effects being nausea (affecting approximately 40% of patients at the therapeutic dose, typically transient), flushing, and headache. The drug is administered as a subcutaneous injection at least 45 minutes before anticipated sexual activity, with a recommendation of no more than one dose per 24 hours and no more than 8 doses per month. Research into PT-141's broader applications continues, including investigations into male erectile dysfunction, female sexual arousal disorder, and hemorrhagic shock where melanocortin agonism has shown protective cardiovascular effects.

Citations

Published findings on PT-141 from peer-reviewed journals.

Research Assistant
Hey, I'm the PepSpace research assistant. Ask me anything about peptides and I'll do my best to help.